HOME | CONTACT US

DIABETES - prevention and management

Diabetes doesn't kill you suddenly, but high blood sugars gradually damage all the blood vessels throughout the body, sometimes for years before you get diagnosed. Diabetes is also associated with the other silent killers of hypertension and high cholesterol. 

BioMonde's response!
The Global Burden of Diabetes

Diabetes is the 4th leading cause of global annual deaths by disease affecting 246 million people worldwide and is expected to affect 380 million by 2025 with growing prevalence's in developing countries. Each year a further 7 million people develop diabetes, 50% of all diabetics are unaware of their condition, and 3.8 million annually.

Problems associated with Chemotherapy treatments 
Hepatotoxicity;
Secondary neoplasms;
Nausea and vomiting;
Diarrhea or constipation;
Anemia;
Malnutrition;
Memory loss;
Immune system depression;
Hemorrhage;
Cardiotoxicity;
Nephrotoxicity;
Ototoxicity;
Death.
Common Diabetes Treatments

Sulfonylureas:
Glimepiride (Amaryl)
Glipizide(Glucotrol/Glucotrol XL)
Glibenclamide (Glyburide, DiaBeta, Micronase)
Biguanides:
Metformin (Glucophage, Glucophage XR)
Sulfonylurea/Biguanide combination:
Glyburide and Metformin (Glucovance)
Alpha-glucosidase inhibitors:
Acarbose (Precose)
Miglitol (Glyset)
Thiazolidinediones:
Pioglitazone (Actos)
Rosiglitazone (Avandia)
Meglitinides:
Repaglinide (Prandin)
Nateglinide (Starlix)

   

4-mu

Development of a optimized, safe, effective and affordable class of novel antidiabetic-prophylaxis and anti-diabetic umbelliferone derivatives (4-meythylumbelliferone).

  • a adminiculum to Glibenclamide treatment;
  • a therapy for diabetes mellitus type II;
  • a therapy for HIV and ARV induced diabetes  mellitus type II;
  • a preventive (anti-diabetic) therapy for non-diabetics.

BioMonde is focused on the prevention and management of Diabetes, and improving the viability and effectiveness of existing anti-diabetic treatments such as Glibenclamide and their adverse affects. As more than 50% of diabetes is not diagnosed, there is a need for a preventive therapy that is readily available and does not have adverse side effects. This is especially true of induced diabetes caused by HIV, drugs, cholesterol, and hypertension. Consequently, BioMonde's approach means that more diabetics and potential diabetic patients have access to effective healthcare.

REFERENCE MATERIAL

Published and  Peer Reviewed Studies click-here


View our product pipeline click-here

Products containing umbelliferone derivatives (4-Methylumbelliferone) click-here

HEPARVIT™ ProDB


Glibenclamide

glibenclamide


Medical research...........

Indicates that umbelliferone derivatives (4-meythylumbellierone) administered as a preventive or management therapy, with or without anti-diabetic Glibenclamide treatment improves several underlying symptoms associated with diabetes.

  • has a antihyperglycemic effect that is comparable with glibenclamide;
  • significantly decreases levels of blood glucose and HbA1c and activities of glucose-6-phosphatase;
  • elevates levels of plasma insulin, Hb, and liver glycogen and activities of glucokinase and
    glucose-6-phosphate dehydrogenase to near normal levels;
  • a significant effect on glycemic control in non-diabetics.